Delta Financial Group Inc. Invests $1.85 Million in Novo Nordisk A/S (NYSE:NVO)

Delta Financial Group Inc. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 21,469 shares of the company’s stock, valued at approximately $1,847,000.

A number of other hedge funds also recently modified their holdings of NVO. Cabot Wealth Management Inc. lifted its holdings in Novo Nordisk A/S by 2.4% in the fourth quarter. Cabot Wealth Management Inc. now owns 121,195 shares of the company’s stock valued at $10,425,000 after buying an additional 2,848 shares during the period. MONECO Advisors LLC lifted its holdings in Novo Nordisk A/S by 19.5% in the fourth quarter. MONECO Advisors LLC now owns 2,359 shares of the company’s stock valued at $203,000 after buying an additional 385 shares during the period. Tradewinds Capital Management LLC lifted its holdings in Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock valued at $429,000 after buying an additional 124 shares during the period. Cohen Capital Management Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at $227,000. Finally, Indie Asset Partners LLC lifted its holdings in Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after buying an additional 126 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 5.2 %

Shares of NVO stock opened at $88.07 on Friday. Novo Nordisk A/S has a 52-week low of $77.82 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a 50-day simple moving average of $86.01 and a two-hundred day simple moving average of $108.07. The company has a market capitalization of $395.19 billion, a price-to-earnings ratio of 26.77, a PEG ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on NVO. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.